Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Upgrades Esperion Therapeutics to Neutral

JP Morgan analyst Jessica Fye upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underweight to Neutral.

byBenzinga Newsdesk

May 5, 2022

1 minute read

JP Morgan analyst Jessica Fye upgrades Esperion Therapeutics (NASDAQ:ESPR) from Underweight to Neutral.

Analyst Ratings

Expert Ratings for United Therapeutics

By Benzinga Insights

Today, 3:43 PM

Within the last quarter, United Therapeutics (NASDAQ:UTHR) has observed the following analyst ratings:

UTHR

Needham Maintains Buy on DraftKings, Lowers Price Target to $32

By Benzinga Newsdesk

Today, 3:43 PM

Needham analyst Bernie McTernan maintains DraftKings (NASDAQ:DKNG) with a Buy and lowers the price target from $46 to $32.

DKNG

Climb Global Solutions Q4 EPS $1.06 Up From $0.78 YoY, Sales $88.91M Beat $84.64M Estimate

By Michael Horton

Today, 3:43 PM

Climb Global Solutions (NASDAQ:CLMB) reported quarterly earnings of $1.06 per share. This is a 35.9 percent increase over earnings of $0.78 per share from the same period last year. The company reported quarterly sales

CLMB

Lordstown Motors Q3 Highlights: Breaking Down Cash Balance, Plant Sale, Production Timeline

By Chris Katje

Today, 3:43 PM

Automotive company Lordstown Motors (NASDAQ: RIDE) reported its third-quarter financial results after close Thursday and provided a company update on its timeline.

RIDE

JP Morgan Upgrades Esperion Therapeutics to Neutral

Related Posts

Expert Ratings for United Therapeutics

Needham Maintains Buy on DraftKings, Lowers Price Target to $32

Climb Global Solutions Q4 EPS $1.06 Up From $0.78 YoY, Sales $88.91M Beat $84.64M Estimate

Lordstown Motors Q3 Highlights: Breaking Down Cash Balance, Plant Sale, Production Timeline